Novo Nordisk enters Capital Markets Day week holding 38.8% of the US branded obesity market
Eli Lilly's own numbers put Novo at 38.8% of the US branded obesity market versus Lilly's 60.9%, the backdrop for Novo's rebrand and its Sept. 21 strategy day.
Novo Nordisk said on Monday it is rebranding as "Novo" and overhauling its corporate culture as it tries to win back share in the obesity drug market from Eli Lilly [1]. The move lands a week before the company's Capital Markets Day on Sept. 21, where CEO Mike Doustdar is expected to spell out changes to the business strategy [1].
The competitive gap is stark. In the second quarter, Novo held 38.8% of the US branded obesity market against Lilly's 60.9%, according to a Lilly earnings presentation citing IQVIA data [1]. "Branded" is the key word: those figures cover the approved, brand-name products, not the compounded copies that some patients have used.
Novo's stock tells a similar story. Shares are down about 15% this year, CNBC reported [1]. STAT put the decline at nearly 20% over the past year, part of a broader slide from the company's 2024 peak, when it was Europe's most valuable company [2]. The two figures cover different time windows, so they are not directly comparable.
What Novo is actually changing
For now, the announced changes are about identity and internal operations rather than products. Novo Nordisk stays the legal name; "Novo" becomes the brand [1]. The company paired the change with the slogan "Lasting Health Starts Now," which it described as a push to build trust with the public and bring "breakthrough science closer to people's daily lives" [1].
Novo also laid out four operating principles: putting patients first in innovation, raising performance to "create greater value for all stakeholders," setting clearer priorities and simpler workflows, and never compromising on patient safety and ethics [1]. Doustdar told CNBC the rebrand and culture shift are "part of the same package," adding that the last four or five years "made us reflect how we need to readjust and rethink about the next decade to come" [1]. STAT described the effort as an attempt to signal the company will "move ahead with greater focus, speed, and impact" [2].
The backdrop includes setbacks in the pipeline. CNBC reported Novo recently scrapped three trials of an experimental cardiovascular drug [1]; STAT reported the company stopped two cardiovascular trials of a drug aimed at lowering inflammation [2]. The sources differ on the count, and neither piece resolves the discrepancy.
One bright spot: the oral version of Wegovy (semaglutide in pill form) surpassed 3 million prescriptions as of June, and it reached the market ahead of Lilly's weight-loss pill Foundayo (orforglipron) [1]. Novo's tirzepatide rivals from Lilly are Mounjaro and Zepbound; Novo's semaglutide products are Ozempic, Wegovy and Rybelsus.
Why it matters for patients
Market share numbers are not a measure of which drug works better for any individual. They do, however, shape the environment patients deal with. When one company holds roughly six of every ten branded obesity prescriptions, it has more leverage in negotiations with insurers and pharmacy benefit managers, and the trailing company has more reason to compete on price, direct-to-consumer offers and access programs. CNBC noted that Novo's new culture principles are aimed at an increasingly competitive market where more of its products have gone direct-to-consumer [1].
The pipeline matters too. Investors have pressed Novo to deliver new blockbuster products [1], and trials that get stopped are future options that disappear. For patients, the practical read is that the menu of approved obesity medicines over the next few years depends on what survives development at both companies.
What the rebrand does not change, based on these sources, is any drug's price, label, supply or coverage. Nothing in either report describes a change to what patients pay or how prescriptions are filled.
What happens next
Sept. 21, 2026: Novo's Capital Markets Day, where Doustdar is set to detail the strategy changes [1]. Whether that plan includes anything on pricing, access or new obesity candidates is not yet known from these sources.
Any shift in the 38.8%-versus-60.9% split will show up in the companies' next quarterly results and the IQVIA data they cite [1].
Sources
Semaglutides.org is for information only and is not medical advice. Always talk to a licensed healthcare provider about your own care. Some links to telehealth services are affiliate links, labeled where they appear.